A carregar...
Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients
BACKGROUND: In Poland, natalizumab or fingolimod treatment can be delivered as a second-line therapy to those patients with relapsing-remitting multiple sclerosis (RRMS) who demonstrated no response to interferon or glatiramer acetate treatment for a minimum of one year. The objective of this study...
Na minha lista:
| Publicado no: | Med Sci Monit |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5115216/ https://ncbi.nlm.nih.gov/pubmed/27829656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.898270 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|